Tag Archive for: CNS

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

/in

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and bring BRIUMVI® (ublituximab) to patients in Australia  Sydney, Australia and Düsseldorf, Germany – 22 July 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on […]

Read more

Neuraxpharm and Dizlin Pharmaceuticals Announce Global Strategic Co-Development Agreement Bringing Next-Generation Drug-Device Therapy to Patients with Advanced Parkinson’s Disease

/in

Infudopa SubC® is a user-friendly and minimally invasive alternative enabling flexible dosing and thereby empowering patients with greater independence Düsseldorf, Germany and Gothenburg, Sweden – 8 July 2025 – Neuraxpharm Group (“Neuraxpharm”), a leading European specialty pharmaceutical company dedicated to central nervous system (CNS) disorders, and Dizlin Pharmaceuticals AB (“Dizlin”), a Swedish R&D company focused […]

Read more

Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®

/in

Barcelona, Spain and Düsseldorf, Germany – 7 January 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end of December 2024 Provigil® (modafinil) and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness […]

Read more

Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies

/in

New therapies will allow patients greater choice and flexibility in the control of CNS disorders Barcelona, Spain / Düsseldorf, Germany and Athens, Greece – 12 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and Pharmathen, one of the largest pharmaceutical companies in […]

Read more

Leriglitazone has met the primary endpoint in NEXUS, the pivotal trial for pediatric patients with cerebral Adrenoleukodystrophy

/in

Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025. Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous […]

Read more